Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole vs Other Atypical Antipsychotics in Schizophrenia with Metabolic Syndrome
NCT00508157Phase 4Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2007
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 4, randomised, open-label trial of aripiprazole in schizophrenia (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (HDL) Cholesterol at 16 weeks. Started Nov 2007; status: terminated.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00508157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00508157.